Valamehr Bahram's Insider Trades & SAST Disclosures
Valamehr Bahram's most recent trade in Fate Therapeutics Inc was a trade of 1,300,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Jan. 16, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Valamehr Bahram.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Fate Therapeutics Inc | Bahram Valamehr | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jan 2025 | 1,300,000 | 1,300,000 | - | - | Stock Option (Right to Buy) | |
| Fate Therapeutics Inc | Bahram Valamehr | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 1.54 per share. | 10 Jan 2025 | 8,705 | 349,364 (0%) | 0% | 1.5 | 13,406 | Common Stock |
| Fate Therapeutics Inc | Bahram Valamehr | Chief R&D Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jul 2024 | 200,000 | 358,069 (0%) | 0% | 0 | Common Stock | |
| Fate Therapeutics Inc | Valamehr Bahram | Chief R&D Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 450,000 | 450,000 | - | - | Stock Option (Right to Buy) | |
| Fate Therapeutics Inc | Valamehr Bahram | Chief R&D Officer | Sale of securities on an exchange or to another person at price $ 4.38 per share. | 09 Jan 2024 | 11,271 | 158,069 (0%) | 0% | 4.4 | 49,367 | Common Stock |
| Fate Therapeutics Inc | Bahram Valamehr | Chief R&D Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2023 | 450,000 | 450,000 | - | - | Stock Option (Right to Buy) | |
| Fate Therapeutics Inc | Bahram Valamehr | Chief R&D Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.37 per share. | 12 Jan 2023 | 423 | 169,340 (0%) | 0% | 1.4 | 580 | Common Stock |
| Fate Therapeutics Inc | Bahram Valamehr | Chief R&D Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jan 2023 | 423 | 0 | - | - | Stock Option (Right to Buy) | |
| Fate Therapeutics Inc | Bahram Valamehr | Chief R&D Officer | Sale of securities on an exchange or to another person at price $ 5.24 per share. | 10 Jan 2023 | 10,917 | 168,917 (0%) | 0% | 5.2 | 57,205 | Common Stock |
| Fate Therapeutics Inc | Bahram Valamehr | Chief R&D Officer | Sale of securities on an exchange or to another person at price $ 30.23 per share. | 07 Jul 2022 | 17,158 | 179,834 (0%) | 0% | 30.2 | 518,686 | Common Stock |
| Fate Therapeutics Inc | Bahram Valamehr | Chief R&D Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jul 2022 | 17,158 | 13,156 | - | - | Stock Option (Right to Buy) | |
| Fate Therapeutics Inc | Bahram Valamehr | Chief R&D Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.73 per share. | 07 Jul 2022 | 17,158 | 196,992 (0%) | 0% | 2.7 | 46,841 | Common Stock |
| Fate Therapeutics Inc | Bahram Valamehr | Chief R&D Officer | Sale of securities on an exchange or to another person at price $ 30.07 per share. | 06 Jul 2022 | 7,842 | 179,834 (0%) | 0% | 30.1 | 235,809 | Common Stock |
| Fate Therapeutics Inc | Bahram Valamehr | Chief R&D Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jul 2022 | 5,842 | 30,314 | - | - | Stock Option (Right to Buy) | |
| Fate Therapeutics Inc | Bahram Valamehr | Chief R&D Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.73 per share. | 06 Jul 2022 | 5,842 | 187,676 (0%) | 0% | 2.7 | 15,949 | Common Stock |
| Fate Therapeutics Inc | Bahram Valamehr | Chief R&D Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.84 per share. | 06 Jul 2022 | 2,000 | 181,834 (0%) | 0% | 4.8 | 9,680 | Common Stock |
| Fate Therapeutics Inc | Bahram Valamehr | Chief R&D Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jul 2022 | 2,000 | 8,704 | - | - | Stock Option (Right to Buy) | |
| Fate Therapeutics Inc | Bahram Valamehr | Chief R&D Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2022 | 25,000 | 36,156 | - | - | Stock Option (Right to Buy) | |
| Fate Therapeutics Inc | Bahram Valamehr | Chief R&D Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.73 per share. | 14 Mar 2022 | 25,000 | 204,834 (0%) | 0% | 2.7 | 68,250 | Common Stock |
| Fate Therapeutics Inc | Bahram Valamehr | Chief R&D Officer | Sale of securities on an exchange or to another person at price $ 30.36 per share. | 14 Mar 2022 | 16,678 | 188,156 (0%) | 0% | 30.4 | 506,344 | Common Stock |
| Fate Therapeutics Inc | Bahram Valamehr | Chief R&D Officer | Sale of securities on an exchange or to another person at price $ 31.66 per share. | 14 Mar 2022 | 3,067 | 185,089 (0%) | 0% | 31.7 | 97,101 | Common Stock |
| Fate Therapeutics Inc | Bahram Valamehr | Chief R&D Officer | Sale of securities on an exchange or to another person at price $ 33.30 per share. | 14 Mar 2022 | 2,960 | 179,934 (0%) | 0% | 33.3 | 98,568 | Common Stock |
| Fate Therapeutics Inc | Bahram Valamehr | Chief R&D Officer | Sale of securities on an exchange or to another person at price $ 32.49 per share. | 14 Mar 2022 | 2,195 | 182,894 (0%) | 0% | 32.5 | 71,316 | Common Stock |
| Fate Therapeutics Inc | Bahram Valamehr | Chief R&D Officer | Sale of securities on an exchange or to another person at price $ 34.04 per share. | 14 Mar 2022 | 100 | 179,834 (0%) | 0% | 34.0 | 3,404 | Common Stock |
| Fate Therapeutics Inc | Bahram Valamehr | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2022 | 53,058 | 53,058 | - | - | Stock Option (Right to Buy) | |
| Fate Therapeutics Inc | Bahram Valamehr | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2022 | 33,302 | 179,834 (0%) | 0% | 0 | Common Stock | |
| Fate Therapeutics Inc | Bahram Valamehr | Chief R&D Officer | Sale of securities on an exchange or to another person at price $ 48.44 per share. | 11 Jan 2022 | 4,152 | 146,950 (0%) | 0% | 48.4 | 201,123 | Common Stock |
| Fate Therapeutics Inc | Bahram Valamehr | Chief R&D Officer | Sale of securities on an exchange or to another person at price $ 49.12 per share. | 11 Jan 2022 | 418 | 146,532 (0%) | 0% | 49.1 | 20,532 | Common Stock |
| Fate Therapeutics Inc | Bahram Valamehr | Chief R&D Officer | Sale of securities on an exchange or to another person at price $ 46.33 per share. | 10 Jan 2022 | 5,245 | 151,453 (0%) | 0% | 46.3 | 243,001 | Common Stock |
| Fate Therapeutics Inc | Bahram Valamehr | Chief R&D Officer | Sale of securities on an exchange or to another person at price $ 47.17 per share. | 10 Jan 2022 | 351 | 151,102 (0%) | 0% | 47.2 | 16,557 | Common Stock |
| Fate Therapeutics Inc | Bahram Valamehr | Chief R&D Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.73 per share. | 13 Dec 2021 | 25,000 | 181,698 (0%) | 0% | 2.7 | 68,250 | Common Stock |
| Fate Therapeutics Inc | Bahram Valamehr | Chief R&D Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Dec 2021 | 25,000 | 61,156 | - | - | Stock Option (Right to Buy) | |
| Fate Therapeutics Inc | Bahram Valamehr | Chief R&D Officer | Sale of securities on an exchange or to another person at price $ 48.75 per share. | 13 Dec 2021 | 7,718 | 158,298 (0%) | 0% | 48.8 | 376,253 | Common Stock |
| Fate Therapeutics Inc | Bahram Valamehr | Chief R&D Officer | Sale of securities on an exchange or to another person at price $ 46.72 per share. | 13 Dec 2021 | 7,018 | 172,580 (0%) | 0% | 46.7 | 327,881 | Common Stock |
| Fate Therapeutics Inc | Bahram Valamehr | Chief R&D Officer | Sale of securities on an exchange or to another person at price $ 47.61 per share. | 13 Dec 2021 | 6,564 | 166,016 (0%) | 0% | 47.6 | 312,512 | Common Stock |
| Fate Therapeutics Inc | Bahram Valamehr | Chief R&D Officer | Sale of securities on an exchange or to another person at price $ 45.68 per share. | 13 Dec 2021 | 2,100 | 179,598 (0%) | 0% | 45.7 | 95,928 | Common Stock |
| Fate Therapeutics Inc | Bahram Valamehr | Chief R&D Officer | Sale of securities on an exchange or to another person at price $ 49.27 per share. | 13 Dec 2021 | 1,600 | 156,698 (0%) | 0% | 49.3 | 78,832 | Common Stock |
| Fate Therapeutics Inc | Bahram Valamehr | Chief R&D Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Nov 2021 | 60,958 | 156,698 (0%) | 0% | 0 | Common Stock | |
| Fate Therapeutics Inc | Bahram Valamehr | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.73 per share. | 13 Sep 2021 | 25,000 | 120,740 (0%) | 0% | 2.7 | 68,250 | Common Stock |
| Fate Therapeutics Inc | Bahram Valamehr | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Sep 2021 | 25,000 | 86,156 | - | - | Stock Option (Right to Buy) | |
| Fate Therapeutics Inc | Bahram Valamehr | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 65.94 per share. | 13 Sep 2021 | 15,809 | 104,931 (0%) | 0% | 65.9 | 1,042,414 | Common Stock |
| Fate Therapeutics Inc | Bahram Valamehr | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 66.84 per share. | 13 Sep 2021 | 8,391 | 96,540 (0%) | 0% | 66.8 | 560,879 | Common Stock |
| Fate Therapeutics Inc | Bahram Valamehr | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 67.46 per share. | 13 Sep 2021 | 800 | 95,740 (0%) | 0% | 67.5 | 53,965 | Common Stock |
| Fate Therapeutics Inc | Bahram Valamehr | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.90 per share. | 15 Mar 2021 | 25,000 | 120,740 (0%) | 0% | 2.9 | 72,500 | Common Stock |
| Fate Therapeutics Inc | Bahram Valamehr | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2021 | 25,000 | 16,156 | - | - | Stock Option (Right to Buy) | |
| Fate Therapeutics Inc | Bahram Valamehr | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 91.94 per share. | 15 Mar 2021 | 8,416 | 108,367 (0%) | 0% | 91.9 | 773,782 | Common Stock |
| Fate Therapeutics Inc | Bahram Valamehr | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 92.64 per share. | 15 Mar 2021 | 8,404 | 99,963 (0%) | 0% | 92.6 | 778,578 | Common Stock |
| Fate Therapeutics Inc | Bahram Valamehr | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 90.89 per share. | 15 Mar 2021 | 3,957 | 116,783 (0%) | 0% | 90.9 | 359,654 | Common Stock |
| Fate Therapeutics Inc | Bahram Valamehr | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 93.75 per share. | 15 Mar 2021 | 3,205 | 96,758 (0%) | 0% | 93.7 | 300,461 | Common Stock |
| Fate Therapeutics Inc | Bahram Valamehr | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 94.59 per share. | 15 Mar 2021 | 1,018 | 95,740 (0%) | 0% | 94.6 | 96,297 | Common Stock |
| Fate Therapeutics Inc | Bahram Valamehr | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jan 2021 | 18,013 | 95,740 (0%) | 0% | 0 | Common stock | |
| Fate Therapeutics Inc | Bahram Valamehr | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jan 2021 | 6,851 | 6,851 | - | - | Stock Option (right to buy) | |
| Fate Therapeutics Inc | Bahram Valamehr | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 117.60 per share. | 08 Jan 2021 | 2,756 | 84,455 (0%) | 0% | 117.6 | 324,103 | Common stock |
| Fate Therapeutics Inc | Bahram Valamehr | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 117.15 per share. | 08 Jan 2021 | 2,451 | 82,004 (0%) | 0% | 117.2 | 287,144 | Common stock |
| Fate Therapeutics Inc | Bahram Valamehr | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 111.62 per share. | 08 Jan 2021 | 1,332 | 79,649 (0%) | 0% | 111.6 | 148,673 | Common stock |
| Fate Therapeutics Inc | Bahram Valamehr | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 110.76 per share. | 08 Jan 2021 | 1,051 | 78,598 (0%) | 0% | 110.8 | 116,407 | Common stock |
| Fate Therapeutics Inc | Bahram Valamehr | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 115.80 per share. | 08 Jan 2021 | 872 | 81,132 (0%) | 0% | 115.8 | 100,977 | Common stock |
| Fate Therapeutics Inc | Bahram Valamehr | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 109.65 per share. | 08 Jan 2021 | 871 | 77,727 (0%) | 0% | 109.7 | 95,509 | Common stock |
| Fate Therapeutics Inc | Bahram Valamehr | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 114.75 per share. | 08 Jan 2021 | 151 | 80,981 (0%) | 0% | 114.8 | 17,328 | Common stock |
| Fate Therapeutics Inc | Bahram Valamehr | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.90 per share. | 14 Dec 2020 | 25,000 | 112,211 (0%) | 0% | 2.9 | 72,500 | Common stock |
| Fate Therapeutics Inc | Bahram Valamehr | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Dec 2020 | 25,000 | 41,156 | - | - | Stock Option (right to buy) | |
| Fate Therapeutics Inc | Bahram Valamehr | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 96.65 per share. | 14 Dec 2020 | 11,765 | 98,633 (0%) | 0% | 96.7 | 1,137,141 | Common stock |
| Fate Therapeutics Inc | Bahram Valamehr | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 99.77 per share. | 14 Dec 2020 | 3,822 | 88,717 (0%) | 0% | 99.8 | 381,315 | Common stock |
| Fate Therapeutics Inc | Bahram Valamehr | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 98.80 per share. | 14 Dec 2020 | 3,148 | 92,539 (0%) | 0% | 98.8 | 311,013 | Common stock |
| Fate Therapeutics Inc | Bahram Valamehr | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 97.70 per share. | 14 Dec 2020 | 2,946 | 95,687 (0%) | 0% | 97.7 | 287,812 | Common stock |
| Fate Therapeutics Inc | Bahram Valamehr | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 95.89 per share. | 14 Dec 2020 | 1,813 | 110,398 (0%) | 0% | 95.9 | 173,857 | Common stock |
| Fate Therapeutics Inc | Bahram Valamehr | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 102.06 per share. | 14 Dec 2020 | 1,006 | 87,311 (0%) | 0% | 102.1 | 102,675 | Common stock |
| Fate Therapeutics Inc | Bahram Valamehr | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 100.97 per share. | 14 Dec 2020 | 400 | 88,317 (0%) | 0% | 101.0 | 40,388 | Common stock |
| Fate Therapeutics Inc | Bahram Valamehr | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 102.75 per share. | 14 Dec 2020 | 100 | 87,211 (0%) | 0% | 102.8 | 10,275 | Common stock |
| Fate Therapeutics Inc | Bahram Valamehr | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.90 per share. | 14 Sep 2020 | 21,924 | 112,211 (0%) | 0% | 2.9 | 63,580 | Common stock |
| Fate Therapeutics Inc | Bahram Valamehr | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Sep 2020 | 21,924 | 66,156 | - | - | Stock Option (right to buy) | |
| Fate Therapeutics Inc | Bahram Valamehr | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 36.03 per share. | 14 Sep 2020 | 16,784 | 94,827 (0%) | 0% | 36.0 | 604,654 | Common stock |
| Fate Therapeutics Inc | Bahram Valamehr | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 36.93 per share. | 14 Sep 2020 | 7,016 | 87,811 (0%) | 0% | 36.9 | 259,085 | Common stock |
| Fate Therapeutics Inc | Bahram Valamehr | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Sep 2020 | 3,076 | 0 | - | - | Stock Option (right to buy) | |
| Fate Therapeutics Inc | Bahram Valamehr | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.69 per share. | 14 Sep 2020 | 3,076 | 90,287 (0%) | 0% | 1.7 | 5,198 | Common stock |
| Fate Therapeutics Inc | Bahram Valamehr | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 37.49 per share. | 14 Sep 2020 | 600 | 87,211 (0%) | 0% | 37.5 | 22,494 | Common stock |
| Fate Therapeutics Inc | Bahram Valamehr | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 34.65 per share. | 14 Sep 2020 | 600 | 111,611 (0%) | 0% | 34.7 | 20,792 | Common stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges